Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 11, 2009, Pages 1809-1815

  Coppola, A ^a   Margaglione, M ^b,c   Santagostino, E ^d   Rocino, A ^e   Grandone, E ^c   Mannucci, P M ^d   Di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e San Giovanni Bosco Hospital   (Italy)

Author keywords

F8 gene mutations; Hemophilia; Immune tolerance induction; Inhibitors; Prognostic factors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANTIBODY TITER; ARTICLE; BREAKTHROUGH BLEEDING; CHILD; DISEASE SEVERITY; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; GENETIC RISK; GENOTYPE; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE INDUCTION; IMMUNOTHERAPY; INTRON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE;

AUTOANTIBODIES; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ITALY; MUTATION; PROGNOSIS; REGISTRIES; TREATMENT OUTCOME;

EID: 70449416200     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03615.x     Document Type: Article

References (38)

1. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008, 14(Suppl. 3):10-18.
2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-63.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia: a systematic review. Haemophilia 2003, 9:418-35.
4. Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008, 14(Suppl. 3):36-42.
5. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006, 12(Suppl. 6):54-61.
6. Rodriguez-Merchan EC, Hedner U, Heijnen L, Jimenez-Yuste V, Lee CA, Morfini M, Querol F, Rosendaal G, Santagostino E, Solimeno LP. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia 2008, 14(Suppl. 6):68-81.
7. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-54.
8. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12:154-62.
9. Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, Stieltjes N, Dolan G, Tusell J. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007, 13:606-12.
10. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007, 13(Suppl. 1):1-22.
11. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003, 9:436-63.
12. DiMichele D, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006, 4:2271-3.
13. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007, 13(Suppl. 5):73-7.
14. Mariani G, Kroner B. Immune tolerance in haemophilia with inhibitors: predictors of success. Haematologica 2001, 86:1186-93.
15. Lenk H. The German registry of immune tolerance treatment in haemophilia - 1999 update. Haematologica 2000, 85:45-7.
16. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002, 87:52-7.
17. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999, 77(Suppl. 1):33-7.
18. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: mutation type determines the risk of inhibitor formation. Thromb Haemost 1995, 74:1402-6.
19. Goodeve AC, Peake IR. The molecular basis of haemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003, 29:23-30.
20. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia 2006, 12(Suppl. 6):15-22.
21. Repessé Y, Slaoui M, Ferrandiz D, Gautier P, Costa C, Costa JM, Lavergne JM, Borel-Derlon A. Factor VIII (FVIII) gene mutations in 120 patients with haemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost 2007, 5:1469-76.
22. Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, Tagliaferri A, Zanon E, Bicocchi MP, Castaldo G, Peyvandi F, Santacroce R, Torricelli F, Grandone E, Mannucci PM. The Italian AICE-Genetics haemophilia A database: results and correlation with clinical phenotype. Haematologica 2008, 93:722-8.
23. ter Avest P, Fischer K, Mancuso ME, Santagostino E, Jiménez Yuste V, van den Berg HM, van der Bom J. Risk stratification for inhibitor development at first treatment for severe haemophilia A patients: a tool for clinical practice. J Thromb Haemost 2008, 6:2048-54.
24. Boekhorst J, Lari GR, d'Oiron R, Costa JM, Nováková IRO, Ala FA, Lavergne JM, van Heerde WL. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008, 14:729-35.
25. Oldenburg J, Albert T, Schröder J, Aburubaiha Z, Müller-Reible C, Schwaab R. Classification of factor VIII gene mutations according to risk of inhibitor formation. Haemophilia 2008, 14(Suppl. 2):58. [Abstract]
26. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in haemophilia A patients with high responding inhibitors. Haematologica 2006, 91:558-61.
27. Salviato R, Bellini D, Radossi P, Sartori R, Pierobon F, Zanotto D, Zanon E, Castaman G, Gandini G, Tagariello G. F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors. Haemophilia 2007, 13:361-72.
28. Gringeri A, Mannucci PM. Italian guidelines for diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005, 11:611-19.
29. Pagani F, Baralle F. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004, 5:389-96.
30. Smith MP, Spence KJ, Waters EL, Beresford R, Mitchell MJ, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999, 81:35-8.
31. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999, 77(Suppl. 1):49-54.
32. Peyvandi F, Jayandharan G, Chandi M, Srivastava A, Nakaya SM, Johnson MJ, Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia 2006, 12(Suppl. 3):82-9.
33. Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM. Immune tolerance induction with a high-purity von Willebrand/factor VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007, 13:373-9.
34. Grenninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008, 14:295-302.
35. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 2006, 107:46-51.
36. Gouw SC, van derBom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 2007, 109:4648-54.
37. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII in black patients with haemophilia. N Engl J Med 2009, 360:1618-27.
38. Reipert BM, van den Helden PMW, Schwarz H-P, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2006, 136:12-25.